Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann C Collier

Showing results (81-90 of 184) with videos related to

Pageof 19
Sort By:
Brain, Behavior, & Immunity - Health|September 30, 2021
Higher levels of plasma inflammation biomarkers are associated with depressed mood and quality of life in aging, virally suppressed men, but not women, with HIVRonald J Ellis, Scott L Letendre, J Hampton Atkinson, et al.
Journal of Neurovirology|December 13, 2005
Clinical validation of the NeuroScreenRonald J Ellis, Scott R Evans, David B Clifford, et al.
Antiviral Therapy|May 17, 2014
Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013Joanne D Stekler, Jennifer McKernan, Ross Milne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2013
Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabineKimberly Y Smith, Camlin Tierney, Katie Mollan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2017
Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysisAlexander J Stockdale, Matthew J Saunders, Mark A Boyd, et al.
Bioresearch Open Access|February 11, 2016
A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons LearnedAnn C Collier, Tae-Wook Chun, Janine Maenza, et al.
AIDS (London, England)|September 24, 2016
Long-term body composition changes in antiretroviral-treated HIV-infected individualsPhilip M Grant, Douglas Kitch, Grace A McComsey, et al.
Archives of Neurology|January 16, 2008
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous systemScott Letendre, Jennifer Marquie-Beck, Edmund Capparelli, et al.
Plos One|June 7, 2013
Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine designPratima Kunwar, Natalie Hawkins, Warren L Dinges, et al.
AIDS (London, England)|February 9, 2012
Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentrationDavid Croteau, Brookie M Best, Scott Letendre, et al.
Pageof 19

Showing results (81-90 of 184) with videos related to

Sort By:
Pageof 19
Brain, Behavior, & Immunity - Health|September 30, 2021
Higher levels of plasma inflammation biomarkers are associated with depressed mood and quality of life in aging, virally suppressed men, but not women, with HIVRonald J Ellis, Scott L Letendre, J Hampton Atkinson, et al.
Journal of Neurovirology|December 13, 2005
Clinical validation of the NeuroScreenRonald J Ellis, Scott R Evans, David B Clifford, et al.
Antiviral Therapy|May 17, 2014
Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013Joanne D Stekler, Jennifer McKernan, Ross Milne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2013
Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabineKimberly Y Smith, Camlin Tierney, Katie Mollan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2017
Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysisAlexander J Stockdale, Matthew J Saunders, Mark A Boyd, et al.
Bioresearch Open Access|February 11, 2016
A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons LearnedAnn C Collier, Tae-Wook Chun, Janine Maenza, et al.
AIDS (London, England)|September 24, 2016
Long-term body composition changes in antiretroviral-treated HIV-infected individualsPhilip M Grant, Douglas Kitch, Grace A McComsey, et al.
Archives of Neurology|January 16, 2008
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous systemScott Letendre, Jennifer Marquie-Beck, Edmund Capparelli, et al.
Plos One|June 7, 2013
Superior control of HIV-1 replication by CD8+ T cells targeting conserved epitopes: implications for HIV vaccine designPratima Kunwar, Natalie Hawkins, Warren L Dinges, et al.
AIDS (London, England)|February 9, 2012
Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentrationDavid Croteau, Brookie M Best, Scott Letendre, et al.
Pageof 19